Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Glenn Errington

Allergy & Immunology Charlotte, NC Medical Doctor

NPI 1942236013 CMS profile 133433

2600 E 7Th St, Unit A, Charlotte, NC 28204

Open in the dashboard

General payments

$9,832

424 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Glenn Errington of Charlotte, NC is reported in the CMS Open Payments database as having received $9,832 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $237 2
2022 General $2,534 110
2021 General $2,309 111
2020 General $1,594 84
2019 General $3,158 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glenn Errington
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Glenn Errington were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Glenn Errington Allergy & Immunology median Middle half National median
2019 $3,158 $594 $163–$1,512 $163
2020 $1,594 $426 $106–$1,233 $114
2021 $2,309 $638 $157–$1,708 $132
2022 $2,534 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $237 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $2,688 89 payments
  2. GlaxoSmithKline, LLC. $1,205 68 payments
  3. Genzyme Corporation $1,124 38 payments
  4. Pfizer Inc. $549 27 payments
  5. Grifols USA, LLC $470 30 payments
  6. Regeneron Healthcare Solutions, Inc. $438 15 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $376 16 payments
  8. ALK-Abello, Inc $336 14 payments
  9. Genentech USA, Inc. $333 13 payments
  10. kaleo, Inc. $323 17 payments
  11. Other $1,990 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $9,832 424 payments
Products named General payments · program years 2019–2024
  1. FASENRA Respiratory $1,009 27 payments
  2. DUPIXENT Immunology $736 27 payments
  3. FASENRA Respiratory $602 26 payments
  4. NUCALA Immunology $560 27 payments
  5. DUPIXENT Immunology $478 16 payments
  6. NUCALA Respiratory $474 27 payments
  7. DUPIXENT Inflammation And Immunology $438 15 payments
  8. TEZSPIRE $339 7 payments
  9. EUCRISA $329 15 payments
  10. AUVI-Q $323 17 payments
  11. Other $5,135 242 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record